NCT04421027 · BASELINE

Baseline characteristics

A Study of Baricitinib (LY3009104) in Participants With COVID-19 · Source last updated 2022-07-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
761
group Id
BG001
value
764
group Id
BG002
value
1525
units
Participants

groups

description
Placebo administered orally QD with standard of care.
id
BG000
title
Placebo +SOC
description
4 mg baricitinib administered orally QD with standard of care.
id
BG001
title
Baricitinib + SOC
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
13.8
value
57.5
group Id
BG001
spread
14.3
value
57.8
group Id
BG002
spread
14.1
value
57.6
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
288
group Id
BG001
value
274
group Id
BG002
value
562
title
Female
measurements
group Id
BG000
value
473
group Id
BG001
value
490
group Id
BG002
value
963
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
168
group Id
BG001
value
148
group Id
BG002
value
316
title
American Indian or Alaska Native
measurements
group Id
BG000
value
94
group Id
BG001
value
80
group Id
BG002
value
174
title
Asian
measurements
group Id
BG000
value
2
group Id
BG001
value
3
group Id
BG002
value
5
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
36
group Id
BG001
value
39
group Id
BG002
value
75
title
Black or African American
measurements
group Id
BG000
value
440
group Id
BG001
value
480
group Id
BG002
value
920
title
White
measurements
group Id
BG000
value
1
group Id
BG001
value
2
group Id
BG002
value
3
title
More than one race
measurements
group Id
BG000
value
20
group Id
BG001
value
12
group Id
BG002
value
32
title
Unknown or Not Reported
description
American Indian or Alaska Native category includes participants from Mexico and Latin America.
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
8
group Id
BG002
value
11
title
Puerto Rico
categories
measurements
group Id
BG000
value
101
group Id
BG001
value
107
group Id
BG002
value
208
title
Argentina
categories
measurements
group Id
BG000
value
155
group Id
BG001
value
154
group Id
BG002
value
309
title
United States
categories
measurements
group Id
BG000
value
19
group Id
BG001
value
19
group Id
BG002
value
38
title
Japan
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
4
group Id
BG002
value
11
title
United Kingdom
categories
measurements
group Id
BG000
value
31
group Id
BG001
value
19
group Id
BG002
value
50
title
India
categories
measurements
group Id
BG000
value
54
group Id
BG001
value
58
group Id
BG002
value
112
title
Russia
categories
measurements
group Id
BG000
value
42
group Id
BG001
value
45
group Id
BG002
value
87
title
Spain
categories
measurements
group Id
BG000
value
20
group Id
BG001
value
16
group Id
BG002
value
36
title
South Korea
categories
measurements
group Id
BG000
value
165
group Id
BG001
value
172
group Id
BG002
value
337
title
Brazil
categories
measurements
group Id
BG000
value
143
group Id
BG001
value
138
group Id
BG002
value
281
title
Mexico
categories
measurements
group Id
BG000
value
10
group Id
BG001
value
15
group Id
BG002
value
25
title
Italy
param Type
COUNT_OF_PARTICIPANTS
title
Region of Enrollment
unit Of Measure
Participants

population Description

All participants randomly assigned to study intervention. Participants were analyzed according to the intervention to which they were assigned.

Complete source fields

denoms

counts
group Id
BG000
value
761
group Id
BG001
value
764
group Id
BG002
value
1525
units
Participants

groups

description
Placebo administered orally QD with standard of care.
id
BG000
title
Placebo +SOC
description
4 mg baricitinib administered orally QD with standard of care.
id
BG001
title
Baricitinib + SOC
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
13.8
value
57.5
group Id
BG001
spread
14.3
value
57.8
group Id
BG002
spread
14.1
value
57.6
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
288
group Id
BG001
value
274
group Id
BG002
value
562
title
Female
measurements
group Id
BG000
value
473
group Id
BG001
value
490
group Id
BG002
value
963
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
168
group Id
BG001
value
148
group Id
BG002
value
316
title
American Indian or Alaska Native
measurements
group Id
BG000
value
94
group Id
BG001
value
80
group Id
BG002
value
174
title
Asian
measurements
group Id
BG000
value
2
group Id
BG001
value
3
group Id
BG002
value
5
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
36
group Id
BG001
value
39
group Id
BG002
value
75
title
Black or African American
measurements
group Id
BG000
value
440
group Id
BG001
value
480
group Id
BG002
value
920
title
White
measurements
group Id
BG000
value
1
group Id
BG001
value
2
group Id
BG002
value
3
title
More than one race
measurements
group Id
BG000
value
20
group Id
BG001
value
12
group Id
BG002
value
32
title
Unknown or Not Reported
description
American Indian or Alaska Native category includes participants from Mexico and Latin America.
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
8
group Id
BG002
value
11
title
Puerto Rico
categories
measurements
group Id
BG000
value
101
group Id
BG001
value
107
group Id
BG002
value
208
title
Argentina
categories
measurements
group Id
BG000
value
155
group Id
BG001
value
154
group Id
BG002
value
309
title
United States
categories
measurements
group Id
BG000
value
19
group Id
BG001
value
19
group Id
BG002
value
38
title
Japan
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
4
group Id
BG002
value
11
title
United Kingdom
categories
measurements
group Id
BG000
value
31
group Id
BG001
value
19
group Id
BG002
value
50
title
India
categories
measurements
group Id
BG000
value
54
group Id
BG001
value
58
group Id
BG002
value
112
title
Russia
categories
measurements
group Id
BG000
value
42
group Id
BG001
value
45
group Id
BG002
value
87
title
Spain
categories
measurements
group Id
BG000
value
20
group Id
BG001
value
16
group Id
BG002
value
36
title
South Korea
categories
measurements
group Id
BG000
value
165
group Id
BG001
value
172
group Id
BG002
value
337
title
Brazil
categories
measurements
group Id
BG000
value
143
group Id
BG001
value
138
group Id
BG002
value
281
title
Mexico
categories
measurements
group Id
BG000
value
10
group Id
BG001
value
15
group Id
BG002
value
25
title
Italy
param Type
COUNT_OF_PARTICIPANTS
title
Region of Enrollment
unit Of Measure
Participants

population Description

All participants randomly assigned to study intervention. Participants were analyzed according to the intervention to which they were assigned.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice